Thursday, June 18, 2026
ASCO 2026 pharmaceutical event banner
← Back to Events
Tier 1 Global Networking: High ONCOLOGY CONCLUDED

ASCO 2026 — McCormick Place, Chicago, United States

The 2026 ASCO Annual Meeting is The Place to Be. Learn more about the sessions, speakers, and science that will be presented at this year's meeting below. Answer who/what/when/where for ASCO 2026 Program pdf with verified dates, location, and what B2B readers should watch. ASCO 2

McCormick Place, Chicago, United States June 5 – June 9, 2026
45,000+ Attendees
9 Presentations
7 Companies
7 Drugs
All Events

Presentation data updated Jun 5, 2026, 9:21 AM UTC

Nova Event Impact Score
59 /100
  • Media coverage 10/20
  • Speaker quality 20/20
  • Pipeline relevance 2/20
  • Historical influence 13/20
  • Company participation 14/20

Key Takeaways

Key Themes

oncologycongressPipeline announcementsPartnership deals

Key Companies

Gilead SciencesAmgenMerck & Co.Johnson & JohnsonPfizer

Key Drugs

pembrolizumabsotorasibsacituzumab tirumotecanamivantamabpumitamig

Key Markets

US Americas

Key Opportunities

Partnership dealsLicensing discussionsVendor selection
Best for
Oncology BD teams Clinical development leaders Investors & analysts

Key Data to Watch

Presentations ranked by investor impact score

ORAL Jun 5

Phase III RASolute 303 trial of sotorasib in first-line KRAS G12C-mutated non-small cell lung cancer: early response rate data

Amgen$AMGN sotorasib(Lumakras) Phase Iii Non-small cell lung cancer
INVESTOR IMPACT: ★★★★★ 5/5
LATE-BREAKER Jun 7

Updated overall survival data from the Phase III KEYNOTE-789 trial of pembrolizumab in non-small cell lung cancer

Merck & Co.$MRK pembrolizumab(Keytruda) Phase Iii Non-small cell lung cancer
INVESTOR IMPACT: ★★★★★ 5/5
ORAL Jun 8

Phase III data of sacituzumab tirumotecan in triple-negative breast cancer

Gilead Sciences$GILD sacituzumab tirumotecan(Trodelvy) Phase Iii Triple-negative breast cancer
INVESTOR IMPACT: ★★★★★ 5/5
ORAL Jun 5

Updated results from the open-label Phase I/Ib CHRYSALIS-2 study (NCT04077463) of amivantamab and lazertinib in non-small cell lung cancer

INVESTOR IMPACT: ★★★★☆ 4/5
POSTER Jun 6

Phase II data of pumitamig in relapsed/refractory multiple myeloma

Pfizer$PFE pumitamig Phase Ii Multiple myeloma
INVESTOR IMPACT: ★★☆☆☆ 2/5
ORAL

Data for amivantamab in lung cancer

Johnson & Johnson$JNJ amivantamab non-small cell lung cancer
INVESTOR IMPACT: ★★☆☆☆ 2/5
ORAL

Data for lazertinib in lung cancer

Johnson & Johnson$JNJ lazertinib non-small cell lung cancer
INVESTOR IMPACT: ★★☆☆☆ 2/5
ORAL

Data for sacituzumab tirumotecan in lung cancer

Merck$MRK sacituzumab tirumotecan non-small cell lung cancer
INVESTOR IMPACT: ★★☆☆☆ 2/5
POSTER Jun 6

Phase I data of silevertinib in EGFR-mutant non-small cell lung cancer

Kelun-Biotech silevertinib Phase I Non-small cell lung cancer
INVESTOR IMPACT: ★☆☆☆☆ 1/5